TIMP1 and CLDN23 may contribute to adenoma-to-colorectal cancer progression and nominate ruxolitinib for repurposing

Colorectal cancer (CRC) may develop through the conventional adenoma-to-carcinoma sequence or alternative routes of carcinogenesis, accompanied by changes in epithelial cell states and remodeling of the tumor microenvironment, yet its core driving mechanisms and therapeutic options remain unclear. This study integrated single-cell, bulk transcriptomic, and spatial transcriptomic datasets for comprehensive bioinformatics analyses, followed by validation in CRC cells and clinical samples using immunohistochemistry. Epithelial cells showed the most pronounced transcriptional and cell-communication remodeling during adenoma-to-carcinoma progression, with marked expansion of tumor-related subpopulations including tumor epithelial cells, stem-like tumor cells, and proliferating tumor cells. Multi-omics integration identified tissue inhibitor of metalloproteinase 1 (TIMP1) and claudin-23 (CLDN23) as core genes closely linked to inflammatory, immune, and metabolic pathways. Ruxolitinib was predicted to target the TIMP1/CLDN23 regulatory network, and in vitro experiments confirmed that it downregulated TIMP1, upregulated CLDN23, and suppressed CRC cell proliferation. Functional assays further showed that TIMP1 promoted while CLDN23 inhibited CRC cell proliferation and migration, and that the two genes may act cooperatively through their shared downstream molecule selenium-binding protein 1 (SELENBP1). These findings suggest an epithelial-centered mechanism of adenoma-to-CRC progression, identify TIMP1 and CLDN23 as molecules with diagnostic, prognostic, and therapeutic potential, and provide preliminary support for repurposing Ruxolitinib in CRC.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-18
DOI
https://doi.org/10.1016/j.tranon.2026.103116
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TIMP1 and CLDN23 may contribute to adenoma-to-colorectal cancer progression and nominate ruxolitinib for repurposing

Penghang Lin, Guangwei Zhu, Chunlin Lin, fangqiu ruan et al.
4 links
Translational Oncology
Colorectal Cancer Treatments and Studies
article

TIMP1 and CLDN23 may contribute to adenoma-to-colorectal cancer progression and nominate ruxolitinib for repurposing

Penghang Lin, Guangwei Zhu, Chunlin Lin, fangqiu ruan, Jie Li, Jianxin Ye, Yan Lin, Weilong Li, Songyi Liu, Yuexin Lin, Shuyuan Zhang, Zhixiong Liu
article en

Abstract

Colorectal cancer (CRC) may develop through the conventional adenoma-to-carcinoma sequence or alternative routes of carcinogenesis, accompanied by changes in epithelial cell states and remodeling of the tumor microenvironment, yet its core driving mechanisms and therapeutic options remain unclear. This study integrated single-cell, bulk transcriptomic, and spatial transcriptomic datasets for comprehensive bioinformatics analyses, followed by validation in CRC cells and clinical samples using immunohistochemistry. Epithelial cells showed the most pronounced transcriptional and cell-communication remodeling during adenoma-to-carcinoma progression, with marked expansion of tumor-related subpopulations including tumor epithelial cells, stem-like tumor cells, and proliferating tumor cells. Multi-omics integration identified tissue inhibitor of metalloproteinase 1 (TIMP1) and claudin-23 (CLDN23) as core genes closely linked to inflammatory, immune, and metabolic pathways. Ruxolitinib was predicted to target the TIMP1/CLDN23 regulatory network, and in vitro experiments confirmed that it downregulated TIMP1, upregulated CLDN23, and suppressed CRC cell proliferation. Functional assays further showed that TIMP1 promoted while CLDN23 inhibited CRC cell proliferation and migration, and that the two genes may act cooperatively through their shared downstream molecule selenium-binding protein 1 (SELENBP1). These findings suggest an epithelial-centered mechanism of adenoma-to-CRC progression, identify TIMP1 and CLDN23 as molecules with diagnostic, prognostic, and therapeutic potential, and provide preliminary support for repurposing Ruxolitinib in CRC.

Translational OncologyVol. 75
Fujian Medical University (CN), First Affiliated Hospital of Fujian Medical University (CN)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon